EUVIMEDEUVIMED entdecken
Crossref

Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study

Jonathan Q Trinh, Ying Xiong, Lynette M Smith, Omar Abughanimeh, Alissa S Marr, Apar K Ganti

Anticancer Research · 2024

DOI: 10.21873/anticanres.16849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Jonathan Q Trinh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, U.S.A.; jtrinh@unmc.edu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The PACIFIC trial demonstrated improved survival in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following definitive concurrent chemoradiotherapy (CRT). This study sought to explore real-world outcomes with durvalumab consolidation therapy at our institution. PATIENTS AND METHODS: We retrospectively identified patients diagnosed with stage III NSCLC at our institution from January 2012 to January 2022. We created two cohorts: one who received durvalumab following definitive CRT and a historical one who did not. Primary outcomes of interest included median progression-free survival (PFS) and overall survival (OS). Additionally, we performed subgroup analysis on the durvalumab cohort to explore the associations between survival and time to durvalumab initiation, PD-L1 expression, and neutrophil-to-lymphocyte ratio (NLR). RESULTS: We identified 79 patients with locally advanced NSCLC who were not surgical candidates. Patients treated with durvalumab (n=44) had significantly improved survival compared to the historical cohort (n=35) including a median PFS of 17.4 months versus 8.0 months (p=0.0019) and a median OS of 37.0 months versus 17.0 months (log-rank p-value=0.07, Wilcoxon p-value=0.02). Within the durvalumab group, outcomes did not significantly differ between those who initiated therapy before or after 42 days of finishing CRT, between various PD-L1 expression levels, or between high or low NLR. CONCLUSION: Patients who received durvalumab as consolidation therapy following definitive CRT demonstrated significantly improved survival compared to a historical cohort who did not receive durvalumab. Furthermore, durvalumab appears to benefit patients regardless of time to initiation, PD-L1 expression, or NLR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalHumansB7-H1 AntigenRetrospective Studies

Stichwörter der Autor:innen

PD-L1Stage III non-small cell lung cancerdurvalumabimmunotherapyneutrophil-to-lymphocyte ratio

Substanzen

durvalumabB7-H1 AntigenAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, U.S.A.; jtrinh@unmc.edu.
  • Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, U.S.A.
  • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, U.S.A.
  • Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, U.S.A.
  • Department of Internal Medicine, VA Nebraska Western Iowa Health System, Omaha, NE, U.S.A.

Zitieren

APA

Trinh, J. Q., Xiong, Y., Smith, L. M., Abughanimeh, O., Marr, A. S., & Ganti, A. K. (2024). Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study. Anticancer Research. https://doi.org/10.21873/anticanres.16849

Vancouver

Trinh JQ, Xiong Y, Smith LM, Abughanimeh O, Marr AS, Ganti AK. Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study. Anticancer Research. 2024. doi:10.21873/anticanres.16849

BibTeX
@article{Trinh2024,
  author = {Trinh, Jonathan Q and Xiong, Ying and Smith, Lynette M and Abughanimeh, Omar and Marr, Alissa S and Ganti, Apar K},
  title = {Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16849}
}
Kostenlos starten →